Social isolation runs with roughly a 29 percent higher risk of death. The figure is the pooled result of Julianne Holt-Lunstad’s meta-analysis, 70 studies and 3.4 million people followed for an average of seven years, and it is the number the longevity internet quietly declines to sell you. Living alone came in higher, at 32 percent. Loneliness, the felt version, at 26.

The most underpriced longevity intervention available to an operator in Singapore is the one that cannot be bottled: structured, repeated, in-person human contact. The peptide clinics on Orchard Road can price a S$400 blood panel because a panel is a product. A room of people on a Tuesday is not, which is precisely why it stays cheap and overlooked.

The most underpriced longevity intervention available to an operator in Singapore is the one that cannot be bottled: structured, repeated, in-person human contact.

The evidence is worth grading before anyone spends on it. The 29 percent gets marketed as the equivalent of smoking fifteen cigarettes a day; that comparison is a translation of effect size into a scarier unit, drawn from Holt-Lunstad’s earlier 2010 work, and it flatters the certainty. This is observational data, Level 2 at best. Isolation predicts death across large cohorts. No randomised trial has shown it causes death, and part of the arrow runs backwards, since the already ill withdraw from company first.

The sturdier finding sits one layer up, in what people believe about their own ageing. Becca Levy’s group tracked more than 11,000 older Americans for up to twelve years and found 45 percent improved in cognition or physical function over the window rather than declined. The ones who improved were disproportionately the ones who held positive beliefs about growing old, after adjusting for age, sex, education, chronic disease and depression. It was published in Geriatrics this year. Belief, like company, is not something a pharmacy stocks.

Singapore is where the arithmetic bites first. The share of citizens over 65 rose from 13.1 percent in 2015 to 20.7 percent in 2025, and reaches 23.9 percent by 2030, one in four. Duke-NUS followed more than 3,000 older Singaporeans: at sixty, those who felt lonely lived three to five fewer years than never-lonely peers, and three to five fewer of those years in active health. The city is rich, fast, and ageing into one of Asia’s loneliest demographics at the same time.

China is the same equation with two more zeros. It carries more than 260 million people over sixty, a generation of empty-nesters left behind by migration, urbanisation and the one-child policy, ageing without family in the next room. Beijing’s response, in January 2024, was the Opinions on Developing a Silver Economy, the first national document to treat elderly well-being as an industry to build. The silver economy was already RMB 5.4 trillion in 2020. The market is being priced; the loneliness underneath it mostly is not.

The public word for all this is prevention. The private word is that nobody has worked out how to charge for it.

The public word for all this is prevention. The private word is that nobody has worked out how to charge for it. A structure that would is not exotic: a membership guaranteeing a fixed cadence of small in-person gatherings rather than one annual gala, premium formats for principals who will pay for a room of genuine peers, corporate programmes that treat loneliness-at-work as the health line it already is on the balance sheet. The dose is the product. Twelve evenings a year, attended, is a specification.

The boundary between this and the wellness grift is measurement. A membership that promises longevity has crossed it. A membership that promises a counted number of hours in a room with other people, and reports attendance the way a clinic reports adherence, has stayed on the right side of it. The evidence underwrites the dose, never the miracle.1

A panel is drawn alone and read alone. The other intervention, the one with better numbers than most of the supplement drawer, only works if two people keep sitting at the same table on a Tuesday.

Footnotes

  1. A clinic can bill for the assay whether or not it changes the outcome. No one has yet worked out how to bill for the Tuesday, which is the whole opportunity and the whole problem. ↩